A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Breast CancerColorectal CancerCutaneous MelanomaUveal MelanomaNon-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Turnstone Biologics, Corp.
- Target Recruit Count
- 31
- Registration Number
- NCT05576077
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Phase 1
Terminated
- Conditions
- Cervical CancerSolid TumorMicrosatellite Stable Colorectal CancerCutaneous Squamous Cell CarcinomaMesotheliomaHPV Positive Oropharyngeal Squamous Cell CarcinomaRenal Cell CarcinomaOropharynx CancerMelanoma (Skin)
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Turnstone Biologics, Corp.
- Target Recruit Count
- 27
- Registration Number
- NCT04301011
- Locations
- 🇺🇸
The Billings Clinic, Billings, Montana, United States
🇰🇷National Cancer Center, Ilsandong, Korea, Republic of
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
Phase 1
Withdrawn
- Conditions
- Metastatic MelanomaSquamous Cell Skin Carcinoma
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Turnstone Biologics, Corp.
- Registration Number
- NCT03773744
This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
Phase 1
Terminated
- Conditions
- HPV-Associated Cancers
- Interventions
- Biological: Ad-E6E7Biological: MG1-E6E7Biological: Atezolizumab
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Turnstone Biologics, Corp.
- Target Recruit Count
- 8
- Registration Number
- NCT03618953
- Locations
- 🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸University of Texas-MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦Juravinski Cancer Centre, Hamilton, Ontario, Canada
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Biological: Ad-MAGEA3Biological: MG1-MAGEA3Biological: Pembrolizumab
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Turnstone Biologics, Corp.
- Target Recruit Count
- 16
- Registration Number
- NCT02879760
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Kingston General Hospital, Kingston, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath